Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.

International journal of radiation oncology, biology, physics·2026

Same author

FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer.

Science advances·2026

Same author

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine·2026

Same author

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026

Same author

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden.

Blood neoplasia·2026

Same author

Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Nov 2, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Palliative Radiotherapy for Diffuse Large B-cell Lymphoma.

Christopher M Wright¹, Antony I Koroulakis², Jonathan A Baron¹

¹Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.

Clinical Lymphoma, Myeloma & Leukemia

|June 15, 2021

Summary

This summary is machine-generated.

Radiotherapy (RT) offers palliative care for diffuse large B-cell lymphoma (DLBCL) patients, especially those with recurrent tumors. This review highlights evolving roles for hypofractionated and low-dose RT in managing DLBCL palliation.

Keywords:

Diffuse large B-cell lymphoma Lymphoma Palliation Palliative radiotherapy Radiotherapy

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Nov 2, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

Oncology
Radiation Oncology
Hematology

Background:

Advances in chemoimmunotherapy, targeted agents, stem cell transplants, and cellular therapies have transformed diffuse large B-cell lymphoma (DLBCL) treatment.
Contemporary therapies offer curative intent even in relapsed or refractory settings, leading to improved outcomes.
These advancements have also increased the incidence of recurrent tumors requiring palliative care.

Purpose of the Study:

To review the role of radiotherapy (RT) in the palliation of diffuse large B-cell lymphoma (DLBCL).
To emphasize the emerging applications of hypofractionated RT and low-dose RT for DLBCL palliation.
To discuss commonly encountered clinical scenarios involving RT for DLBCL palliation.

Main Methods:

Literature review of existing studies on radiotherapy for DLBCL palliation.
Focus on hypofractionated and low-dose RT techniques.
Analysis of clinical scenarios and their management with RT.

Main Results:

Radiotherapy is a valuable tool for palliating recurrent DLBCL.
Hypofractionated and low-dose RT show promise in specific DLBCL palliation scenarios.
Evidence supports the use of RT in managing symptoms and improving quality of life for DLBCL patients.

Conclusions:

Radiotherapy plays a crucial role in the palliative management of DLBCL, particularly for recurrent disease.
Evolving RT techniques like hypofractionation and low-dose RT offer new avenues for effective palliation.
Further research into optimal RT strategies for DLBCL palliation is warranted.